Evidence map›Paper›PMID 42344810›Full record

ArticleCureus2026

Neovascular Glaucoma Secondary to Choroidal Metastasis From Lung Adenocarcinoma: A Palliative Management Challenge.

Nur Hanisah Mohamad Kani, Chenshen Lam, Othmaliza Othman

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nur Hanisah Mohamad KaniDepartment of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MYS.
Chenshen LamDepartment of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MYS.
Othmaliza OthmanDepartment of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MYS.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal metastasis is the most common intraocular malignancy in adults and may present as the initial manifestation of an underlying systemic malignancy. We report a case of a 62-year-old woman who presented with unilateral progressive visual deterioration and was initially referred with a working diagnosis of ocular tuberculosis (TB). Ocular examination revealed a non-pigmented choroidal mass with exudative retinal detachment. Subsequent imaging identified a lung lesion, and a primary lung malignancy was suspected based on contrast-enhanced computed tomography of the thorax. Histopathological examination later confirmed lung adenocarcinoma. The choroidal metastasis demonstrated rapid progression, with anterior extension leading to shallowing of the anterior chamber, rubeosis iridis, and eventual development of neovascular glaucoma (NVG) with acute angle closure. The patient developed severe ocular pain with markedly elevated intraocular pressure, which was refractory to maximal medical therapy. Management was guided by the advanced stage of systemic disease and poor visual prognosis. As enucleation was declined by the patient, palliative external beam radiotherapy was performed, resulting in significant symptomatic relief. This case underscores the importance of early consideration of malignancy in atypical choroidal lesions, particularly in TB-endemic settings, and highlights the potential for rapid intraocular progression with significant complications. A multidisciplinary, patient-centred approach with emphasis on symptom palliation is essential in advanced disease.

Indexed as

choroidal metastasislung adenocarcinomaneovascular glaucomaocular metastasispalliative radiotherapy

Identifiers

PMID42344810
PMCPMC13290320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.